Nektar Therapeutics (NASDAQ: NKTR)’s stock price has plunge by -5.86relation to previous closing price of 1.28. Nevertheless, the company has seen a -12.04% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-14 that Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in H1’25. NKTR-255 is showing promising results in multiple oncology trials, although these are only small studies. NKTR-255 also has a potential near-term readout in the JAVELIN Bladder Medley study, although there is competition.
Is It Worth Investing in Nektar Therapeutics (NASDAQ: NKTR) Right Now?
Company’s 36-month beta value is 0.60.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NKTR is 177.81M, and currently, short sellers hold a 2.94% ratio of that floaft. The average trading volume of NKTR on November 14, 2024 was 1.20M shares.
NKTR’s Market Performance
NKTR stock saw a decrease of -12.04% in the past week, with a monthly decline of -12.68% and a quarterly a decrease of -3.60%. The volatility ratio for the week is 5.95%, and the volatility levels for the last 30 days are 6.69% for Nektar Therapeutics (NKTR). The simple moving average for the past 20 days is -9.65% for NKTR’s stock, with a -1.62% simple moving average for the past 200 days.
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with Piper Sandler repeating the rating for NKTR by listing it as a “Overweight.” The predicted price for NKTR in the upcoming period, according to Piper Sandler is $7 based on the research report published on November 04, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $4. The rating they have provided for NKTR stocks is “Buy” according to the report published on September 30th, 2024.
Rodman & Renshaw gave a rating of “Buy” to NKTR, setting the target price at $2 in the report published on June 28th of the current year.
NKTR Trading at -7.01% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.50% of loss for the given period.
Volatility was left at 6.69%, however, over the last 30 days, the volatility rate increased by 5.95%, as shares sank -15.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.41% upper at present.
During the last 5 trading sessions, NKTR fell by -10.58%, which changed the moving average for the period of 200-days by +125.89% in comparison to the 20-day moving average, which settled at $1.3348. In addition, Nektar Therapeutics saw 113.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from Zalevsky Jonathan, who sale 6,866 shares at the price of $1.28 back on Aug 19 ’24. After this action, Zalevsky Jonathan now owns 250,804 shares of Nektar Therapeutics, valued at $8,788 using the latest closing price.
Wilson Mark Andrew, the Chief Legal Officer of Nektar Therapeutics, sale 5,651 shares at $1.28 during a trade that took place back on Aug 19 ’24, which means that Wilson Mark Andrew is holding 225,263 shares at $7,233 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -1.46 for the present operating margin
- 0.73 for the gross margin
The net margin for Nektar Therapeutics stands at -1.81. The total capital return value is set at -0.57. Equity return is now at value -161.63, with -44.87 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -1.63. The debt to equity ratio resting at 2.21. The interest coverage ratio of the stock is -10.63.
Currently, EBITDA for the company is -243.11 million with net debt to EBITDA at -0.55. When we switch over and look at the enterprise to sales, we see a ratio of 3.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.24.
Conclusion
In a nutshell, Nektar Therapeutics (NKTR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
